Kalvista Pharmaceuticals (KALV) Reiterated at Buy at Stifel After 4Q25 Pre-Report
Tweet Send to a Friend
Stifel analyst Paul Matteis reiterated a Buy rating and $39.00 price target on Kalvista Pharmaceuticals Inc (NASDAQ: KALV).The analyst commented ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
